Leqembi
E25439
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
All labels observed (5)
| Label | Occurrences |
|---|---|
| lecanemab | 8 |
| Leqembi canonical | 7 |
| Lecanemab | 2 |
| Leqembi – Alzheimer’s disease | 1 |
| donanemab | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T195379 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Leqembi Context triple: [Biogen, hasProduct, Leqembi]
-
A.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
B.
Kimvita
Kimvita is a major coastal dialect of Swahili spoken primarily in and around Mombasa, Kenya.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Abital
Abital is one of the lesser-known wives of the biblical King David, mentioned in the Hebrew Bible as the mother of his son Shephatiah.
-
E.
Namba
Namba is a major commercial and entertainment district in Osaka, Japan, known for its bustling nightlife, shopping, and iconic neon-lit streets.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Leqembi Target entity description: Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
A.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
B.
Kimvita
Kimvita is a major coastal dialect of Swahili spoken primarily in and around Mombasa, Kenya.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Abital
Abital is one of the lesser-known wives of the biblical King David, mentioned in the Hebrew Bible as the mother of his son Shephatiah.
-
E.
Namba
Namba is a major commercial and entertainment district in Osaka, Japan, known for its bustling nightlife, shopping, and iconic neon-lit streets.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
Alzheimer’s disease drug
ⓘ
drug ⓘ monoclonal antibody ⓘ |
| administeredTo | adult patients ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| belongsToTherapeuticArea |
neurodegenerative diseases
ⓘ
neurology ⓘ |
| coDevelopedBy | Eisai and Biogen ⓘ |
| developedBy |
Biogen
ⓘ
Eisai ⓘ |
| hasATCClass | N06DX ⓘ |
| hasBiomarkerTarget | amyloid-beta protofibrils ⓘ |
| hasBrandOwner | Eisai ⓘ |
| hasCommonAdverseEffect |
ARIA-E (amyloid-related imaging abnormalities with edema)
ⓘ
ARIA-H (amyloid-related imaging abnormalities with microhemorrhages and hemosiderin deposits) ⓘ headache ⓘ infusion-related reactions ⓘ |
| hasContraindicationNote | caution in patients on anticoagulant therapy ⓘ |
| hasCoPromotionPartner | Biogen ⓘ |
| hasCountryOfApproval |
United States
ⓘ
linked to:
United States of America
|
| hasDosageForm | solution for intravenous infusion ⓘ |
| hasDosingFrequency | every two weeks ⓘ |
| hasDrugClass | anti-amyloid beta monoclonal antibody ⓘ |
| hasEffect | slows cognitive decline compared with placebo in early Alzheimer’s disease ⓘ |
| hasFDAIndicationText | treatment of Alzheimer’s disease ⓘ |
| hasGenericName |
lecanemab
ⓘ
linked to:
Leqembi
|
| hasIndication |
Alzheimer’s disease
ⓘ
linked to:
Alzheimer's disease
mild cognitive impairment due to Alzheimer’s disease ⓘ mild dementia stage of Alzheimer’s disease ⓘ |
| hasINN |
lecanemab
ⓘ
linked to:
Leqembi
|
| hasKeyClinicalTrial |
CLARITY AD
ⓘ
Study 201 ⓘ Study 301 ⓘ |
| hasMolecularType | humanized IgG1 monoclonal antibody ⓘ |
| hasRegulatoryPathway | FDA traditional approval ⓘ |
| hasRegulatoryStatus | FDA approved ⓘ |
| hasRouteOfAdministration | intravenous infusion ⓘ |
| hasWarning | risk of ARIA ⓘ |
| indicatedFor | early-stage Alzheimer’s disease ⓘ |
| isAdministeredIn | hospital or infusion center settings ⓘ |
| isFirstInClass | first anti-amyloid Alzheimer’s drug with full FDA approval (as of 2023) ⓘ |
| isUsedWith | MRI monitoring for ARIA ⓘ |
| mechanismOfAction |
binds aggregated soluble and insoluble amyloid-beta
ⓘ
reduces amyloid-beta plaques in the brain ⓘ |
| previouslyHadRegulatoryPathway | FDA accelerated approval ⓘ |
| requires | confirmation of amyloid-beta pathology ⓘ |
| targets |
amyloid-beta
ⓘ
amyloid-beta plaques ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Leqembi Description of subject: Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
Referenced by (19)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: Leqembi
linked to: Leqembi
linked to: Leqembi
linked to: Leqembi
linked to: Leqembi
linked to: Leqembi
linked to: Leqembi
subject linked to:
ARIA-H (amyloid-related imaging abnormalities with microhemorrhages and hemosiderin deposits)
linked to: Leqembi
subject linked to:
ARIA-H (amyloid-related imaging abnormalities with microhemorrhages and hemosiderin deposits)
linked to: Leqembi
linked to: Leqembi